" Increased Adoption of Biologics in Moderate to Severe HS Cases”
- Biologic therapies, particularly adalimumab (Humira), the only FDA-approved biologic for hidradenitis suppurativa (HS), are now standard care for moderate to severe cases, targeting TNF-α to reduce inflammation and lesion formation
- Clinical trials are exploring novel agents like secukinumab (IL-17 inhibitor) and bimekizumab (IL-17A/F inhibitor), with Phase III data showing up to 50% reduction in abscess and nodule counts. These advancements are expanding treatment options beyond traditional antibiotics (e.g., clindamycin) and surgery, aligning with the market’s shift toward precision medicine for chronic inflammatory conditions
- The integration of biologics into HS treatment guidelines, supported by EHSF (European Hidradenitis Suppurativa Foundation), is improving patient outcomes and reducing reliance on invasive procedures
- Ongoing research into IL-23 inhibitors, such as guselkumab, is further diversifying the biologic arsenal, offering hope for refractory cases
- For Instance, In 2024, Novartis’ Phase III SUNSHINE trial for secukinumab demonstrated a 45% HiSCR (Hidradenitis Suppurativa Clinical Response) rate at 16 weeks in moderate to severe HS patients, prompting EMA approval discussions in early 2025
- The growing use of biologics like adalimumab and emerging IL-17/IL-23 inhibitors is transforming HS treatment, improving outcomes for severe cases and fueling market expansion through targeted therapies
